Cargando…

Increasing the uptake in a general practice prostate cancer screening programme

BACKGROUND: Prostate cancer (PC) is the second most common cause of cancer deaths among males worldwide. Prostate-specific antigen (PSA) is a predictive indicator of prostate pathology. Men with elevated PSA levels are at increased risk of developing PC. There is currently no UK national PC screenin...

Descripción completa

Detalles Bibliográficos
Autores principales: Limaye, Neil, Zorzato, Daniele, Nadarajasundaram, Aaruran, Ong, Sabrina B Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915375/
https://www.ncbi.nlm.nih.gov/pubmed/35272998
http://dx.doi.org/10.1136/bmjoq-2021-001701
_version_ 1784668007041073152
author Limaye, Neil
Zorzato, Daniele
Nadarajasundaram, Aaruran
Ong, Sabrina B Y
author_facet Limaye, Neil
Zorzato, Daniele
Nadarajasundaram, Aaruran
Ong, Sabrina B Y
author_sort Limaye, Neil
collection PubMed
description BACKGROUND: Prostate cancer (PC) is the second most common cause of cancer deaths among males worldwide. Prostate-specific antigen (PSA) is a predictive indicator of prostate pathology. Men with elevated PSA levels are at increased risk of developing PC. There is currently no UK national PC screening programme, therefore patients often present to general practices (GPs) at later stages of pathology, worsening patient prognosis and outcomes. LOCAL PROBLEM: The location of the GP surgery had a large patient population at increased risk of PC, namely Afro-Caribbean/Asian males. METHODS: We conducted baseline measurements to identify male patients over the age of 65 and/or male patients who were at high risk of developing PC. These included previous referred patients or patients with a PSA over 10.0. We then implemented three plan-do-study-act (PDSA) cycles and measured their effect after 2 weeks of starting the respective intervention. INTERVENTIONS: PDSA1: Generating a list of target patients who have not had repeat/follow-up/referral and directly contacting by telephone to invite them for a blood test. PDSA2: Creating patient-specific electronic pop-up reminders on the electronic-patient-record system for PSA follow-up/referral/repeat test. Planned PDSA3: Patient education of prostate health and general self-checking, as well as benefits/risks of undergoing PSA screening in the form of patient focus groups and informative leaflets. RESULTS: We identified 220 male patients over 65 registered at a large South London GP surgery. 77.7% of eligible patients had a PSA measurement since 1 April 2019. Our results showed an overall increase in screening of 13.5% from baseline. CONCLUSIONS: Our project identified patients that may potentially have undiagnosed prostate pathology. However, a key factor for not reaching our goal was blood test refusal. This was further exacerbated by the COVID-19 pandemic, impacting the capacity to disseminate appropriate information to the local population on the importance of PSA screening.
format Online
Article
Text
id pubmed-8915375
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-89153752022-03-25 Increasing the uptake in a general practice prostate cancer screening programme Limaye, Neil Zorzato, Daniele Nadarajasundaram, Aaruran Ong, Sabrina B Y BMJ Open Qual Quality Improvement Report BACKGROUND: Prostate cancer (PC) is the second most common cause of cancer deaths among males worldwide. Prostate-specific antigen (PSA) is a predictive indicator of prostate pathology. Men with elevated PSA levels are at increased risk of developing PC. There is currently no UK national PC screening programme, therefore patients often present to general practices (GPs) at later stages of pathology, worsening patient prognosis and outcomes. LOCAL PROBLEM: The location of the GP surgery had a large patient population at increased risk of PC, namely Afro-Caribbean/Asian males. METHODS: We conducted baseline measurements to identify male patients over the age of 65 and/or male patients who were at high risk of developing PC. These included previous referred patients or patients with a PSA over 10.0. We then implemented three plan-do-study-act (PDSA) cycles and measured their effect after 2 weeks of starting the respective intervention. INTERVENTIONS: PDSA1: Generating a list of target patients who have not had repeat/follow-up/referral and directly contacting by telephone to invite them for a blood test. PDSA2: Creating patient-specific electronic pop-up reminders on the electronic-patient-record system for PSA follow-up/referral/repeat test. Planned PDSA3: Patient education of prostate health and general self-checking, as well as benefits/risks of undergoing PSA screening in the form of patient focus groups and informative leaflets. RESULTS: We identified 220 male patients over 65 registered at a large South London GP surgery. 77.7% of eligible patients had a PSA measurement since 1 April 2019. Our results showed an overall increase in screening of 13.5% from baseline. CONCLUSIONS: Our project identified patients that may potentially have undiagnosed prostate pathology. However, a key factor for not reaching our goal was blood test refusal. This was further exacerbated by the COVID-19 pandemic, impacting the capacity to disseminate appropriate information to the local population on the importance of PSA screening. BMJ Publishing Group 2022-03-10 /pmc/articles/PMC8915375/ /pubmed/35272998 http://dx.doi.org/10.1136/bmjoq-2021-001701 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Quality Improvement Report
Limaye, Neil
Zorzato, Daniele
Nadarajasundaram, Aaruran
Ong, Sabrina B Y
Increasing the uptake in a general practice prostate cancer screening programme
title Increasing the uptake in a general practice prostate cancer screening programme
title_full Increasing the uptake in a general practice prostate cancer screening programme
title_fullStr Increasing the uptake in a general practice prostate cancer screening programme
title_full_unstemmed Increasing the uptake in a general practice prostate cancer screening programme
title_short Increasing the uptake in a general practice prostate cancer screening programme
title_sort increasing the uptake in a general practice prostate cancer screening programme
topic Quality Improvement Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8915375/
https://www.ncbi.nlm.nih.gov/pubmed/35272998
http://dx.doi.org/10.1136/bmjoq-2021-001701
work_keys_str_mv AT limayeneil increasingtheuptakeinageneralpracticeprostatecancerscreeningprogramme
AT zorzatodaniele increasingtheuptakeinageneralpracticeprostatecancerscreeningprogramme
AT nadarajasundaramaaruran increasingtheuptakeinageneralpracticeprostatecancerscreeningprogramme
AT ongsabrinaby increasingtheuptakeinageneralpracticeprostatecancerscreeningprogramme